Related references
Note: Only part of the references are listed.PD-L1 (CD274) and PD-L2 (PDCD1LG2) promoter methylation is associated with HPV infection and transcriptional repression in head and neck squamous cell carcinomas
Alina Franzen et al.
ONCOTARGET (2018)
Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer
Seung Tae Kim et al.
NATURE MEDICINE (2018)
PD-1 (PDCD1) Promoter Methylation Is a Prognostic Factor in Patients With Diffuse Lower-Grade Gliomas Harboring Isocitrate Dehydrogenase (IDH) Mutations
Lea Kristin Roever et al.
EBIOMEDICINE (2018)
CTLA4 methylation predicts response to anti-PD-1 and anti-CTLA-4 immunotherapy in melanoma patients
Diane Goltz et al.
JCI INSIGHT (2018)
Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients
Akihito Kawazoe et al.
GASTRIC CANCER (2017)
Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma
Elizabeth D. Thompson et al.
GUT (2017)
PD-L1 (CD274) promoter methylation predicts survival in patients with acute myeloid leukemia
D. Goltz et al.
LEUKEMIA (2017)
Overexpression and gene amplification of PD-L1 in cancer cells and PD-L1+ immune cells in Epstein-Barr virus-associated gastric cancer: the prognostic implications
Ruri Saito et al.
MODERN PATHOLOGY (2017)
PD-L1 (CD274) promoter methylation predicts survival in colorectal cancer patients
Diane Goltz et al.
ONCOIMMUNOLOGY (2017)
Targeting Immune Checkpoints in Cancer Therapy
Suzanne L. Topalian
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer
Anshuman Panda et al.
JNCI-Journal of the National Cancer Institute (2017)
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Yoon-Koo Kang et al.
LANCET (2017)
PDCD1 (PD-1) promoter methylation predicts outcome in head and neck squamous cell carcinoma patients
Diane Goltz et al.
ONCOTARGET (2017)
PD-1 and PD-L1 co-expression predicts favorable prognosis in gastric cancer
Yanhua Wu et al.
ONCOTARGET (2017)
Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma
Hae Il Jung et al.
CANCER RESEARCH AND TREATMENT (2017)
Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer
Anshuman Panda et al.
JNCI-Journal of the National Cancer Institute (2017)
Regulation of PD-L1: a novel role of pro-survival signalling in cancer
J. Chen et al.
ANNALS OF ONCOLOGY (2016)
Programmed Death-Ligand 1 Expression Is Common in Gastric Cancer Associated With Epstein-Barr Virus or Microsatellite Instability
Changqing Ma et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2016)
CDO1 promoter methylation is associated with gene silencing and is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients
Sebastian Meller et al.
EPIGENETICS (2016)
Pembrolizumab (MK-3475) for recurrent or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: Multicohort phase II KEYNOTE-059 study.
Charles S. Fuchs et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort
Laura Q. M. Chow et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
Jonathan E. Rosenberg et al.
LANCET (2016)
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
Kei Muro et al.
LANCET ONCOLOGY (2016)
Prognostic and predictive value of tumor-infiltrating lymphocytes for clinical therapeutic research in patients with non-small cell lung cancer
Dong-Qiang Zeng et al.
ONCOTARGET (2016)
Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers
Sarah Derks et al.
ONCOTARGET (2016)
PD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy
Heidrun Gevensleben et al.
ONCOTARGET (2016)
The clinicopathological and prognostic significance of PD-L1 expression in gastric cancer: a meta-analysis of 10 studies with 1,901 patients
Minghui Zhang et al.
SCIENTIFIC REPORTS (2016)
Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade
Douglas B. Johnson et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Promoter methylation of the immune checkpoint receptor PD-1 (PDCD1) is an independent prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy
Diane Goltz et al.
ONCOIMMUNOLOGY (2016)
CheckMate-032: Phase I/II open-label study of safety and activity of nivolumab (nivo) alone or with ipilimumab (ipi) in advanced and metastatic (A/M) gastric cancer (GC)
Yelena Yuriy Janjigian et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Suzanne L. Topalian et al.
NATURE REVIEWS CANCER (2016)
Comprehensive analyses of tumor immunity: implications for cancer immunotherapy
Bo Li et al.
GENOME BIOLOGY (2016)
Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes
Razvan Cristescu et al.
NATURE MEDICINE (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
Antagonists of PD-1 and PD-L1 in Cancer Treatment
Evan J. Lipson et al.
SEMINARS IN ONCOLOGY (2015)
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
Janis M. Taube et al.
CLINICAL CANCER RESEARCH (2014)
Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
H. Yang et al.
LEUKEMIA (2014)
Comprehensive molecular characterization of gastric adenocarcinoma
Adam J. Bass et al.
NATURE (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
Current questions for the treatment of advanced gastric cancer
A. Cervantes et al.
CANCER TREATMENT REVIEWS (2013)
PTEN Loss Increases PD-L1 Protein Expression and Affects the Correlation between PD-L1 Expression and Clinical Parameters in Colorectal Cancer
Minmin Song et al.
PLOS ONE (2013)
Prognostic significance of tumor-infiltrating T cells in ovarian cancer: A meta-analysis
Wei-Ting Hwang et al.
GYNECOLOGIC ONCOLOGY (2012)
Functions of DNA methylation: islands, start sites, gene bodies and beyond
Peter A. Jones
NATURE REVIEWS GENETICS (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Methylation Subtypes and Large-Scale Epigenetic Alterations in Gastric Cancer
Hermioni Zouridis et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
PD-L2 is expressed on activated human T cells and regulates their function
Nassima Messal et al.
MOLECULAR IMMUNOLOGY (2011)
GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers
Craig H. Mermel et al.
GENOME BIOLOGY (2011)
Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma
Qiang Gao et al.
CLINICAL CANCER RESEARCH (2009)
Oncogenic Pathway Combinations Predict Clinical Prognosis in Gastric Cancer
Chia Huey Ooi et al.
PLOS GENETICS (2009)
PD-1 and its ligands in tolerance and immunity
Mary E. Keir et al.
ANNUAL REVIEW OF IMMUNOLOGY (2008)
PD-L2 expression extends beyond dendritic cells/macrophages to B1 cells enriched forVH11/VH12 and phosphatidylcholine binding
Xuemei Zhong et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2007)
Characterization of human lung tumor-associated fibroblasts and their ability to modulate the activation of tumor-associllited T cells
Michael R. Nazareth et al.
JOURNAL OF IMMUNOLOGY (2007)
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer
Junzo Hamanishi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer
Takeo Nomi et al.
CLINICAL CANCER RESEARCH (2007)
The consensus coding sequences of human breast and colorectal cancers
Tobias Sjoeblom et al.
SCIENCE (2006)
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome
Jerom Galon et al.
SCIENCE (2006)
Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance
Changping Wu et al.
ACTA HISTOCHEMICA (2006)
PD-L2:PD-1 involvement in T cell proliferation, cytokine production, and integrin-mediated adhesion
PA Saunders et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2005)
Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer
Y Ohigashi et al.
CLINICAL CANCER RESEARCH (2005)
B7-h1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression
J Konishi et al.
CLINICAL CANCER RESEARCH (2004)
Differential binding properties of B7-H1 and B7-DC to programmed death-1
P Youngnak et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2003)
Exploration, normalization, and summaries of high density oligonucleotide array probe level data
RA Irizarry et al.
BIOSTATISTICS (2003)
PD-L2 is a second ligand for PD-I and inhibits T cell activation
Y Latchman et al.
NATURE IMMUNOLOGY (2001)
Share Paper
